KLK3 and posterior cortical atrophy: The risk assessment of PCa at diagnosis and after treatment is based on the grading system, the PSA level, the tumor-node-metastasis (TNM) classification, and/or the previous treatment history in order to predict potentially lethal PCa and to inform treatment decisions [29].